Federal Register
Notice: FDA has determined the regulatory review period for the extension of a patent that claims the human drug product for Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide monohydrate) is 3,318 days. The product is indicated for the extension of a patent that claims that human drug product. To view this notice, click here.